Evidence map›Paper›PMID 41127405›Full record

ReviewFrontiers in ophthalmology2025

Iridocorneal endothelial syndrome.

Hua Ma, Mingfang Xia, Qing Gu, Lingling Zheng, Shaoping Ha

Abstract readReview
In one paragraph

Review in Frontiers in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hua Ma *Glaucoma of Ophthalmology, Ningxia Aier Eye Hospital, Yinchuan, Ningxia, China.
Mingfang Xia *Glaucoma of Ophthalmology, Ningxia Aier Eye Hospital, Yinchuan, Ningxia, China.
Qing GuGlaucoma of Ophthalmology, Ningxia Aier Eye Hospital, Yinchuan, Ningxia, China.
Lingling ZhengGlaucoma of Ophthalmology, Ningxia Aier Eye Hospital, Yinchuan, Ningxia, China.
Shaoping HaGlaucoma of Ophthalmology, Ningxia Aier Eye Hospital, Yinchuan, Ningxia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The iridocorneal endothelial syndrome encompasses a spectrum of ocular disorders predominantly affecting one eye in young to middle-aged women, typically without a familial predisposition. The hallmark feature of iridocorneal endothelial syndrome is the migration of corneal endothelial cells towards the iridocorneal angle and onto the iris. This syndrome comprises three distinct clinical variations: progressive essential atrophy of the iris (including corectopia, iris atrophy, or iris hole), Chandler syndrome (characterized by corneal edema with mild to absent changes in the iris), and Cogan-Reese syndrome (manifesting as nodular pigmented lesions on the front surface of the iris). In cases involving corneal manifestations, such as corneal edema or decompensation, options like Descemet's stripping automated endothelial keratoplasty and Descemet membrane endothelial keratoplasty may be considered for optimal management. For instance, conditions affecting the iris, such as an iris cavity, multiple pupils, or photophobia, may make femtosecond-assisted keratopigmentation a treatment option. In cases of glaucoma secondary to iridocorneal endothelial syndrome, trabeculectomy with mitomycin C and the implantation of a glaucoma drainage device have been shown to reduce intraocular pressure effectively. At the same time, retrocorneal membrane interception-enhanced peripheral iridectomy has demonstrated significant efficacy.

Indexed as

Chandler syndromeCogan-Reese syndromeglaucomairidocorneal endothelial syndromeprogressive iris atrophy

Identifiers

PMID41127405
PMCPMC12537377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.